Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity

Nephrology Dialysis Transplantation

Volumn 13, Issue SUPPL. 3, 1998, Pages 23-28

  Naves Díaz, Manuel L ^a   Elorriaga, Rosaria ^a   Canteros, Alejandra ^a   Cannata Andía, Jorge B ^a,b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Alkaline phosphatase activity; Aluminium and iron; Bone cell proliferation; Deferiprone; Desferrioxamine

Indexed keywords

ALKALINE PHOSPHATASE; CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON; MARKER;

BONE CELL; CELL ACTIVITY; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ALKALINE PHOSPHATASE; CELL DIVISION; DEFEROXAMINE; IRON; IRON CHELATING AGENTS; OSTEOBLASTS; PYRIDONES; TUMOR CELLS, CULTURED;

EID: 0031957505     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Moeschlin S, Schnider U. Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new, potent iron eliminating agent [desferrioxamine B]. N Engl J Med 1963; 269: 57-66
2. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenuos desferrioxamine. Lancet 1983; 2: 181-184
3. Olivieri NF, Buncic JR, Chew E et al. Visual and auditory neurotoxicity in patients receiving subcutaneus desferrioxamine infusions. N Engl J Med 1986; 314: 869-873
4. Gallany T, Freedman MH, Vellend H, Francombe W. Yersinia sepsis in patients with iron over load treated with desferrioxamine (letter). N Engl J Med 1986; 314, 1643
5. Veis J, Contiguaglia R, Klein M, Mishel J, Alfrey A, Shapiro JI. Mucormycosis associated with desferrioxamine use in hemodialysis patients (abstract). Kidney Int 1987; 31: 247
6. De Virgilis S, Congia M, Frau F et al. Desferrioxamine-induced growth retardation in patiens with thalassaemia major. J Pediatr 1988; 113: 661-669
7. Boelart JR, de Locht M. Side effects of aluminum - or iron - chelators used in dialysis patients. Nefrologia 1993; 13 [Suppl 3]: 129-132
8. Pippard MJ. Clinical use of iron chelation. In de Sousa M, Brock JH, eds. Iron in Immunity, Cancer and Inflammation. West Sussex: John Wiley and Sons, 1989: 361-392
9. Porter JB, Huehns ER, Hider RC. The development of iron chelating drugs. In: Hershko C, ed. Iron Chelating Therapy. London: Baillière's Tindall, 1989, vol 2: 257-285
10. Olivieri NF, Templenton DM, Koren G et al. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one [L1] in iron-loaded patients. Ann N Y Acad Sci 1990; 612: 369-377
11. Agarwall MB, Gupte SS, Viswanathan C et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82: 460-466
12. Elorriaga R, Fernández Martin JL, Menéndez P, Naves ML, Braga S, Cannata JB. Aluminum removal: short and long-term preliminary results with L1 in rats. Drugs of Today 1992; 28: 177-182
13. Kontoghiorghes GJ, Agarwal MB, Tondury P et al. Future of oral iron chelator deferiprone (L1). Lancet 1993; 341: 1479-1480
14. Kontoghiorghes GJ. Misinformation about deferiprone (L1) (letter). Lancet 1993; 342: 250
15. Berkovitch M, Laxer RM, Inman R et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994; 343: 1471-1472
16. Hunt J, Richards RJ, Harwood R and Jacobs A. The effect of desferrioxamine on fibroblasts and collagen formation in cell cultures. Br J Haematol 1979; 41: 69-76
17. Lederman HM, Cohen A, Lee JWW, Freedman MH and Gelfand EW. Desferrioxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748-753
18. Blatt J, Taylor SR, Kontoghiorghes G. Comparison of activity of desferrioxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res 1989; 49: 2925-2927
19. Tzanno-Martins C, Elorriaga R, Menéndez MJ, Naves ML, McGregor S, Jorgetti V, Cannata JB. Efecto de la desferrioxamina [DFO] sobre la proliferación de osteoblastos. Nefrología 1993; 13 [Suppl 3]: 133-135
20. Tzanno-Martins C, Naves ML, Elorriaga R, Menéndez-Fraga P, Jorgetti V, Cannata JB. Evaluating the effect of desferrioxamine on bone-cell proliferation. Nephrol Dial Transplant 1995; 10: 714-715
21. 3 on differentation of human osteosarcoma [MG-63] cells. J Biol Chem 1992; 267: 8943-8949
22. 3. J Biol Chem 1987; 262: 4165-4171
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
24. 3 on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem 1982; 257: 3362-3365
25. Cannata JB. Utilidad de la desferrioxamina en el diagnóstico y el tratamiento de la intoxicación alumínica. Nefrologia 1992; 12: 295-301
26. Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res 1992; 52: 4591-4599
27. Fernández Martín JL, Menéndez Fraga P, Canteros MA, Diaz López JB, Cannata Andía JB. Binding of aluminum to plasma proteins: comparative effect of desferrioxamine and deferiprone [L1]. Clin Chim Acta 1994; 230: 137-145
28. Elorriaga R, Menéndez P, De la Vega M et al. Bone histological effects of desferrioxamine (DFO) and deferiprone (L1) in aluminum intoxicated rats (abstract). Nephrol Dial Transplant 1996; 11: 1207
29. Kontoghiorghes GJ, Barr J, Bailod RA. Aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one [L1]. Drugs of Today 1992; 28: 183-187
30. Vasilakakis DM, D'Haese PC, Lamberts LV, Lemoniaton E, Digenis P, De Broe ME. Removal of aluminoxamine and ferroxamine by charcoal hemoperfusion and hemodialysis. Kidney Int 1992; 41: 1400-1407
31. Goddard JG, Kontoghiorghes JG. Pharmacological studies of the orally active iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one [L1] in man (abstract). Br J Haematol 1990; 44: 74-75
32. Pattanapanyasat K, Webster HK, Tongtawe P, Kongcharoen P, Hider C. Effect of orally active hydroxypyridone iron chelators on human lymphocyte function. Br J Haematol 1992; 82: 13-19
33. Reichard P, Ehrenberg A. Ribonucleotide reductase - a radical enzyme. Science 1983; 221: 514-519
34. 3 responsive alkaline phosphatase in osteoblast like cells (Ros 17/2. 8, MG-63 and MC3T3) and growth cartilage cells in culture. J Biol Chem 1989; 264: 11879-11886
35. Lajeunesse D. Effect of 17β-estradiol on the human osteosarcoma cell line MG-63. Bone Miner 1994, 24: 1-16